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Characterization of the amino-terminal domain
of Mx2/MxB-dependent interaction
with the HIV-1 capsid
Dear Editor,
More than 50 years have passed since the myxovirus resis-
tance (MX) genes were ﬁrst discovered and found to suppress
infection with inﬂuenza viruses in mice (Lindenmann, 1962).
Likemost mammals, mice carry twoMX genes,MX1 andMX2,
which have arisen by gene duplication; both of these genes
exhibit antiviral activity against a wide range of viruses (Liu
et al., 2013). Humans also have two MX genes, encoding the
MxAandMxBproteins, which are interferon-induced, dynamin-
like large molecular weight guanosine triphosphatases (GTP-
ases). The antiviral functions of MxA have been deeply
explored: MxA can protect cells from infection by multiple
groups of pathogenic DNA andRNAviruses, such as inﬂuenza
A virus and hepatitis B virus (Liu et al., 2013). In contrast, Mx2,
althoughclosely related toMxA (63%aminoacid [aa] sequence
identity), appears to have lost its antiviral function andhas been
recognized as playing other cellular roles, since it does not
suppress the viruses tested (Melen et al., 1996).
Recently, Mx2 has been shown to serve as an inhibitor of
human immunodeﬁciency virus type-1 (HIV-1) (Goujon et al.,
2013; Kane et al., 2013; Liu et al., 2013). Mx2 restricts HIV-1
infectionat a relatively latepost-entryphase (Goujonet al., 2013;
Kane et al., 2013) and leads to a reduced level of integrated viral
DNA (Liu et al., 2013). The N-terminal 91-aa domain of Mx2 has
been identiﬁed as a critical determinant of Mx2’s antiviral activity
(Busnadiego et al., 2014). Interestingly, several mutations in the
HIV-1 viral capsid (CA) region of Gag can overcome Mx2-med-
iated suppression (Goujon et al., 2013; Kane et al., 2013; Liu
et al., 2013).Thus,Mx2maybind to theHIV-1coreand inhibit the
early events in HIV-1 binding, thereby restricting viral infection.
However, there is still no evidence showing that Mx2 directly
binds to the HIV-1 capsid. Whether capsid binding of Mx2
requires cellular co-factors and/or higher-order assemblies of
CA isalsounknown. In this study,wehaveobtainedastableMx2
protein containing the N-terminal 91-aa domain. Furthermore,
we have observed that puriﬁed Mx2 recombinant proteins bind
directly to HIV-1 CA assemblies in vitro. The N-terminal 83-aa
domain of Mx2 is apparently critical for this interaction.
Human MxA and Mx2 share a similar aa sequence and
domain architecture (Liu et al., 2013; Melen et al., 1996). The
crystal structure of MxA indicates that it includes a G domain
that binds and hydrolyzes GTP; a hinge-like “bundle sig-
naling element (BSE)” that connects the G domain to the
elongated stalk domain; and the stalk domain, which is
involved in self-assembly and oligomerization (Gao et al.,
2010; Gao et al., 2011) (Fig. 1A). A unique feature of Mx2 is
that it exhibits a longer N-terminal domain, including an NLS
(N-terminal 25 aa).
To identify the contribution of the diverse Mx2 domains to
capsid binding, we generated and screened a series of deletion
constructs of Mx2 with an N-terminal His-Sumo-tag (Fig. S1A)
and characterized the expression, solubility, stability, and oligo-
merization behavior of these constructs (Table S1). We found
that full-length Mx2 was difﬁcult to obtain in E. coli. The expres-
sion levels of all the other deletion constructs (1–387, 1–413)
were greatly reduced, but Δ1–83 exhibited a highly improved
expression level (Fig. S1B), indicating that the N-terminal 83-aa
domain of Mx2 may cause low expression and instability in
solution (Table S1). Other deletion constructs (84–387, 84–413)
without the N-terminal 83-aa domain showed high expression
levels (Fig. S1B), but it exhibited poor solubility and stability (Fig.
S1C), indicating that thecompletenessofBSEplaysasigniﬁcant
role in maintaining the structure of theMx2 constructs. Thus, we
wereunable toobtain stable constructswith theN-terminal 83-aa
domain.
To overcome this problem, on the basis of previous reports
(Chappieetal., 2010)and thestructureofMxA(Gaoetal.,2011),
we engineered aminimal GTPase-BSE fusion protein (GF) that
connected residues 84–413 and residues 683–715 from human
Mx2 via a ﬂexible linker (Fig. S1A). GF eluted as a monodi-
spersed peak from a size-exclusion column and had much
better solubility (>20 mg/mL) than did residues 84–387 and 84–
413 (Fig. S1C). In the next phase, we added the N-terminal
83-aa domain of Mx2 to GF in order to generate an N-terminal-
GTPase-BSE fusion protein (N-GF). His-Sumo-N-GF showed a
highly improved expression level (>20 mg/L in E. coli) and sol-
ubility when compared to other deletion constructs with the
N-terminal 83-aa domain (Fig. S1C). After removing the Sumo-
tag, we saw a reduction in the stability of the N-GF proteins, but
N-GF eluted as a monodispersed peak from a size-exclusion
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column (Table S1). Thus, we successfully generated a stable
fusion construct of Mx2 for use in detecting further binding.
It had previously been demonstrated that assembled HIV-
1 CA-NC tubular complexes can interact with full-length MX2
and its truncations containing the N-terminal 91-aa (isolated
from HEK293T cell lysates) (Fricke et al., 2014). To further
clarify whether Mx2 directly binds to HIV-1 CA assemblies (at
20 μmol/L) in vitro, we tested puriﬁed His-Sumo-N-GF and
N-GF (79 µmol/L) in precipitation assays with preassembled
CA tubes. The results clearly indicated that the N-GF pro-
teins co-pellet with assembled CA, revealing that the binding
process does not require other cellular co-factors (Fig. 1A);
thus, established that Mx2 directly binds to HIV-1 CA tubes
in vitro.
We performed a further dissection of the interactions
between the Mx2 constructs and CA to address the
contribution of the different Mx2 domains to capsid binding.
Puriﬁed GF, Δ1–83, and the stalk domain (79 μmol/L) were
each tested in the precipitation assay with preassembled CA
tubes (20μmol/L). Essentially nobindingwasobserved forGF,
Δ1–83, or the stalk domain under the same assay conditions
(Fig. 1B). All CA tubes were prepared as previously described
(Yang et al., 20122012; Hung et al., 2013) andwere conﬁrmed
by cryo-electronmicroscopy (cryo-EM) (Fig. 1C). The ﬁndings
described above indicate that Mx2-CA binding requires the
N-terminal 83-aa of Mx2. The N-GF does not contain the stalk
domain, but it is apparently sufﬁcient to bind HIV-1 CA
assembly. On the other hand, the stalk domain alone showed
no binding to the assembled CA tubes (Fig. 1B).
HIV-1 capsid (CA) proteins can assemble into closed
fullerene cones or helical tubes in vivo and in vitro. It is
widely known that tripartite motif protein isoform 5 alpha
A
B























t p s t p s
C
Figure 1. Interactions of Mx2 variants with CA tubular assemblies. (A) Binding of His-sumo-N-GF and N-GF to pre-assembled
wild-type CA tubes. Binding reactions were analyzed by SDS-PAGE using CA tubular assemblies at 80 μmol/L or binding buffer
alone, incubated with His-sumo-N-GF and N-GF (79 μmol/L). Samples of the reaction mixture before centrifugation (t), of the
supernatant (s), and of the pellet (p) are detected alone. (B) Binding of Mx2 constructs to preassembled wild-type CA tubes. Binding
reactions were the same as in (A). No binding of any Mx2 construct without the N-terminal 83-aa domain was found. (C) Cryo-EM
images of pre-assembled wild-type CA tubes used in the Mx2-CA binding experiments.
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(TRIM5α) is an antiviral protein that restricts infection of
HIV-1 by binding to the viral capsid. The TRIM5α-CA binding
interaction requires an assembled capsid lattice, since indi-
vidual CA monomers do not have an appreciable afﬁnity for
TRIM5α (Stremlau et al., 2006). It is the shape of the HIV-1
capsid that is recognized by the TRIM5α protein (Yang et al.,
2012). Having conﬁrmed the binding of Mx2-CA assemblies,
we wanted to investigate whether, like TRIM5α, Mx2 binds to
the viral capsid by recognizing the shape of the higher-order
assembled HIV-1 capsid lattice. Therefore, we over-expres-
sed and puriﬁed individual hexamers (A14C/E45C/W184A/
M185A), pentamers (A21C/E22C/W184A/M185A), and
monomers of CA as previously described (Fig. 2A) (Pornillos
et al., 2011), and separately examined the binding afﬁnity
between each of them and GST-N-GF by GST pull-down
assays, detecting the results by SDS-PAGE. No complex
formation was detected, even at very high concentrations of
both proteins (Fig. 2B). This result demonstrates that Mx2
shows no detectable binding to CA hexamers, pentamers, or
monomers, implying that a higher-order lattice of CA tubes is
required for an efﬁcient Mx2-CA interaction.
In the current study, we have demonstrated for the ﬁrst
time that a direct interaction occurs between Mx2 and the
HIV-1 capsid. The N-terminal region of Mx2 is critical for this
interaction. We identiﬁed a fusion protein of Mx2 containing
the N-terminal 83-aa and the complete BSE (N-GF), which
was fundamental for the detection of Mx2-CA binding in vitro.
The N-GF construct may also facilitate further biochemical
and structural studies of Mx2. The co-pelleting of puriﬁed
N-GF and CA tubes, as well as domain mapping studies,
showed that Mx2 directly recognizes CA assembles through
its N-terminal 83-aa domain. Based on the results of pull-
down assays, Mx2-CA binding requires the higher-order
assembled capsid lattice, just as TRIM5α-CA binding does.
While this work was in progress, it was reported that
assembled HIV-1 CA-NC tubular complexes can co-pellet Mx2
from whole-cell lysates (Fricke et al., 2014). However, there is
no evidence to show that Mx2 directly binds to CA in vitro (i.e.,
whether capsid binding ofMx2 requires co-factors in cells). The
contribution of the NC domain to the binding of Mx2 to higher-
order assemblies of CA-NC was also not clear. Our data argue
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Figure 2. GST Pull-down assays of GST-N-GF with CA hexamers, pentamers, and monomers. (A) Size-exclusion
chromatographic proﬁles of individual CA hexamers, pentamers, and monomers. (B) Pull-down assays of GST-N-GF with CA
hexamers, pentamers, and monomers. CA hexamers, pentamers, and monomers, incubated with GST-N-GF-bound glutathione-
sepharose beads, showed no more interaction than those incubated with glutathione-sepharose beads alone.
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Interestingly, several mutations in the HIV-1 viral capsid (CA)
region of Gag can overcome MX2-mediated suppression
(Fricke et al., 2014; Liu et al., 2013). The CA-NC tubular com-
plexes that are formed with mutations in CA that help HIV-1
escape fromMx2 restriction exhibit weakened interactionswith
Mx2 (Fricke et al., 2014). Thus, Mx2may bind to the HIV-1 core
and inhibit the process of HIV-1 infection.
It has been reported that Mx2 variants Δ572–715 and
Δ623–715 have lost their ability to oligomerize, and they fail to
bind to CA-NC assemblies in vitro (Fricke et al., 2014). Our
results show that although N-GF lacks the stalk domain
involved in oligomerization, it still has the ability to bind CA
tubes. This binding may occur because N-GF has the com-
plete BSE, which is of great importance in maintaining normal
Mx2 structure. These results suggest that although it is pos-
sible that theoligomerization ofMx2producesahigher binding
afﬁnity for the viral capsid, oligomerization is not necessary for
Mx2-CA binding. Future studies will be required to explore the
oligomerization functions that are required for Mx2-mediated
HIV-1 restriction (Haller et al., 2010).
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